Inhibitory effect of Yukmijihwang-tang, a traditional herbal formula against testosterone-induced benign prostatic hyperplasia in rats

BMC Complementary and Alternative Medicine

Volumn 12, Issue , 2012, Pages

  Shin, In S ^a,b   Lee, Mee Y ^a   Ha, Hye K ^a   Seo, Chang S ^a   Shin, Hyeun Kyoo ^a  

^a Korea Institute of Oriental Medicine (KIOM)   (South Korea)

^b Chonnam National University   (South Korea)

Author keywords

Benign prostatic hyperplasia; Dihydrotestosterone; Traditional herbal formula; Yukmijihwang tang

Indexed keywords

ALISMA ORIENTALE EXTRACT; ANDROSTANOLONE; CORNUS OFFICINALIS EXTRACT; CYCLINE; DIOSCOREA BATATAS EXTRACT; HERBACEOUS AGENT; PAEONIA SUFFRUTICOSA EXTRACT; PLANT EXTRACT; PORIA COCOS EXTRACT; REHMANNIA GLUTINOSA EXTRACT; TESTOSTERONE PROPIONATE; UNCLASSIFIED DRUG; WATER; YUKMIJIHWANG TANG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIGEN EXPRESSION; ARTICLE; BODY WEIGHT; CONTROLLED STUDY; DRUG EFFECT; DRUG SYNTHESIS; EPITHELIUM HYPERPLASIA; HISTOPATHOLOGY; HORMONE DETERMINATION; IMMUNOBLOTTING; MALE; NONHUMAN; ORGAN SIZE; PROSTATE HYPERTROPHY; RAT; TISSUE HOMOGENATE;

ANIMALS; DIHYDROTESTOSTERONE; DISEASE MODELS, ANIMAL; DRUGS, CHINESE HERBAL; HUMANS; MALE; PROSTATE; PROSTATIC HYPERPLASIA; RATS; RATS, WISTAR; TESTOSTERONE;

EID: 84862163927     PISSN: None     EISSN: 14726882     Source Type: Journal    
DOI: 10.1186/1472-6882-12-48     Document Type: Article

References (33)

1. Pais P. Potency of a novel saw palmetto extract, SPET-85, for inhibition of 5alpha-reductase II. Adv Ther 2010, 27:555-563. 10.1007/s12325-010-0041-6, 20623347.
2. Roehrborn CG. Male lower urinary tract symptoms (LUTS) and benign prostatic hyperplasia (BPH). Med Clin North Am 2011, 95:87-100. 10.1016/j.mcna.2010.08.013, 21095413.
3. Barkin J. Benign prostatic hyperplasia and lower urinary tract symptoms: evidence and approaches for best case management. Can J Urol 2011, 18:14-19.
4. McVary KT. A review of combination therapy in patients with benign prostatic hyperplasia. Clin Ther 2007, 29:387-398. 10.1016/S0149-2918(07)80077-4, 17577460.
5. Black L, Naslund MJ, Gilbert TD, Davis EA, Ollendorf DA. An examination of treatment patterns and costs of care among patients with benign prostatic hyperplasia. Am J Managed Care 2006, 12:99-110.
6. Roehrborn CG, Rosen RC. Medical therapy options for aging men with benign prostatic hyperplasia: focus on alfusozin 10 mg once daily. Clin Interv Aging 2008, 3:511-524. 2682383, 18982921.
7. Gravas S, Oelke M. Current status of 5alpha-reductase inhibitors in the management of lower urinary tract symptoms and BPH. World J Urol 2010, 28:9-15. 10.1007/s00345-009-0493-y, 2809314, 19956956.
8. Andriole G, Bruchovsky N, Chung LW, Matsumoto AM, Rittmaster R, Roehrborn C, Russell D, Tindall D. Dihydrotestosterone and the prostate: the scientific rationale for 5alpha-reductase inhibitors in the treatment of benign prostatic hyperplasia. J Urol 2004, 172:1399-1403. 10.1097/01.ju.0000139539.94828.29, 15371854.
9. Bullock TL, Andriole GL. Emerging drug therapies for benign prostatic hyperplasia. Expert Opin Emerg Drugs 2006, 11:111-123. 10.1517/14728214.11.1.111, 16503830.
10. Traish AM, Hassani J, Guay AT, Zitzmann M, Hansen ML. Adverse side effects of 5α-reductase inhibitors therapy: persistent diminished libido and erectile dysfunction and depression in a subset of patients. J Sex Med 2011, 8:872-884. 10.1111/j.1743-6109.2010.02157.x, 21176115.
11. Ha H, Lee JK, Lee HY, Seo CS, Lee MY, Huh JI, Shin H. Evaluation of genotoxicity of Yukmijihwang-tang, a herbal formula. Regul Toxicol Pharmacol 2011, 59:391-396. 10.1016/j.yrtph.2011.01.002, 21241764.
12. Ha H, Lee JK, Lee HY, Koh WS, Seo CS, Lee MY, Huang DS, Shin H. Safety evaluation of Yukmijihwang-tang: assessment of acute and subchronic toxicity in rats. Evid Based Complement Alternat Med 2011, 2011:672136. 3017901, 21234385.
13. Song XY, Chen Q, Qi XY. Effects of liuwei dihuang pill on erythrocyte aldose reductase activity in early diabetic nephropathy patients. Zhongguo Zhong Xi Yi Jie He Za Zhi 2004, 24:1087-1090.
14. Kang DG, Sohn EJ, Moon MK, Mun YJ, Woo WH, Kim MK, Lee HS. Yukmijihwang-tang ameliorates ischemia/reperfusion-induced renal injury in rats. J Ethnopharmacol 2006, 104:47-53. 10.1016/j.jep.2005.08.044, 16183223.
15. Kang M, Kim JH, Cho C, Lee KY, Shin M, Hong M, Shim I, Bae H. Effects of Yukmijihwang-tang derivatives (YMJd) on ibotenic acid-induced amnesia in the rat. Biol Pharm Bull 2006, 29:1431-1435. 10.1248/bpb.29.1431, 16819183.
16. Oh MS, Chang MS, Park W, Kim DR, Bae H, Huh Y, Park SK. Yukmijihwang-tang protects against cyclophosphamide-induced reproductive toxicity. Reprod Toxicol 2007, 24:365-370. 10.1016/j.reprotox.2007.05.007, 17624719.
17. Shim KS, Ma CJ, Kim DS, Ma JY. Yukmijihwang-tang inhibits receptor activator for nuclear Factor-κB ligand-induced osteoclast differentiation. J Med Food 2011, 14:1439-1447. 10.1089/jmf.2010.1502, 21883017.
18. Shen JJ, Lin CJ, Hiang JL, Hsieh KH, Kuo ML. The effect of liu-wei-di-huang wan on cytokine gene expression from human peripheral blood lymphocytes. Am J Chin Med 2003, 31:247-257. 10.1142/S0192415X03000886, 12856863.
19. Huynh H. Induction of apoptosis in rat ventral prostate by finasteride is associated with alteration in MAP kinase pathways and Bcl-2 related family of proteins. Int J Oncol 2002, 20:1297-1303.
20. Veeresh Babu SV, Veeresh B, Patill AA, Warke YB. Lauric acid and myristic acid prevent testosterone induced prostatic hyperplasia in rats. Eur J Pharmacol 2010, 625:262-265.
21. Arruzazabala ML, Mas R, Molina V, Noa M, Carbajal D, Mendoza N. Effect of D-004, a lipid extract from the Cuban royal palm fruit, on atypical prostate hyperplasia induced by phynylephrine in rats. Drugs R&D 2006, 7:233-241. 10.2165/00126839-200607040-00003, 3440725, 22977575.
22. Bisson JF, Hidalgo S, Rozan P, Messaoudi M. Therapeutic effect of ACTICOA powder, a cocoa polyphenolic extract on experimentally induced prostate hyperplasia in Wistar-Unilever rats. J Med Food 2007, 10:628-635. 10.1089/jmf.2006.242, 18158833.
23. Jang H, Ha US, Kim SJ, Yoon BI, Han DS, Yuk SM, Kim SW. Anthocyanin extracted from black soybean reduces prostate weight and promotes apoptosis in the prostatic hyperplasia-induced rat model. J Agric Food Chem 2010, 58:12686-12691. 10.1021/jf102688g, 21121678.
24. Essers J, Theil AF, Baldeyron C, van Cappellen WA, Houtsmuller AB, Kanaar R, Vermeulen W. Nuclear dynamics of PCNA in DNA replication and repair. Mol Cell Biol 2005, 25:9350-9359. 10.1128/MCB.25.21.9350-9359.2005, 1265825, 16227586.
25. Li SH, Ryu JH, Park SE, Cho YS, Park JW, Lee WJ, Chun YS. Vitamin C supplementation prevents testosterone-induced hyperplasia of rat prostate by down-regulating HIF-1alpha. J Nutr Biochem 2010, 21:801-808. 10.1016/j.jnutbio.2009.06.004, 19716283.
26. Zhong W, Peng J, He H, Wu D, Han Z, Bi X, Dai Q. Ki-67 and PCNA expression in prostate cancer and benign prostatic hyperplasia. Clin Invest Med 2008, 31:8-15.
27. Vikram A, Kushwaha S, Jena GB. Relative influence of testosterone and insulin in the regulation of prostatic cell proliferation and growth. Steroids 2011, 76:416-423. 10.1016/j.steroids.2010.12.014, 21215763.
28. Miller J, Tarter TH. Combination therapy with dutasteride and tamsulosin for the treatment of symptomatic enlarged prostate. Clin Interv Aging 2009, 4:251-258. 2697590, 19554096.
29. Rittmaster R, Hahn RG, Ray P, Shannon JB, Wurzel R. Effect of dutasteride on intraprostatic androgen levels in men with benign prostatic hyperplasia or prostate cancer. Urology 2008, 72:808-812. 10.1016/j.urology.2008.06.032, 18718641.
30. Carson C, Rittmaster R. The role of dihydrotestosterone in benign prostatic hyperplasia. Urology 2003, 61:2-7.
31. Mizokami A, Koh E, Izumi K, Narimoto K, Takeda M, Honma S, Dai J, Keller ET, Namiki M. Prostate cancer stromal cells and LNCaP cells coordinately activate the androgen receptor through synthesis of testosterone and dihydrotestosterone from dehydroepiandrosterone. Endocr Relat Cancer 2009, 16:1139-1155. 10.1677/ERC-09-0070, 19608712.
32. Tarter TH, Vaughan ED. Inhibitors of 5alpha-reductase in the treatment of benign prostatic hyperplasia. Curr Pharm Des 2006, 12:775-783. 10.2174/138161206776056010, 16515494.
33. Aggarwal S, Thareja S, Verma A, Bhardwaj TR, Kumar M. An overview on 5alpha-reductase inhibitors. Steroids 2010, 75:109-153. 10.1016/j.steroids.2009.10.005, 19879888.